GW Pharmaceuticals PLC closed the most recent trading day at $144.55, moving -1.51% from the previous trading session. This change lagged the S&P 500's 0.07% gain on the day. Elsewhere, the Dow lost 0.21%, while the tech-heavy Nasdaq added 0.13%.
Heading into today, shares of the company had gained 17.09% over the past month, outpacing the Medical sector's gain of 3.05% and the S&P 500's gain of 5.36% in that time.
Investors will be hoping for strength from GWPH as it approaches its next earnings release, which is expected to be February 26, 2019. On that day, GWPH is projected to report earnings of -$2.97 per share, which would represent a year-over-year decline of 22.22%. Meanwhile, our latest consensus estimate is calling for revenue of $9.28 million, up 19.99% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$10.18 per share and revenue of $96.16 million. These totals would mark changes of +3.6% and +467.12%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for GWPH. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.43% higher within the past month. GWPH is holding a Zacks Rank of #2 (Buy) right now.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Image: Bigstock
GW Pharmaceuticals PLC (GWPH) Stock Sinks As Market Gains: What You Should Know
GW Pharmaceuticals PLC closed the most recent trading day at $144.55, moving -1.51% from the previous trading session. This change lagged the S&P 500's 0.07% gain on the day. Elsewhere, the Dow lost 0.21%, while the tech-heavy Nasdaq added 0.13%.
Heading into today, shares of the company had gained 17.09% over the past month, outpacing the Medical sector's gain of 3.05% and the S&P 500's gain of 5.36% in that time.
Investors will be hoping for strength from GWPH as it approaches its next earnings release, which is expected to be February 26, 2019. On that day, GWPH is projected to report earnings of -$2.97 per share, which would represent a year-over-year decline of 22.22%. Meanwhile, our latest consensus estimate is calling for revenue of $9.28 million, up 19.99% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$10.18 per share and revenue of $96.16 million. These totals would mark changes of +3.6% and +467.12%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for GWPH. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.43% higher within the past month. GWPH is holding a Zacks Rank of #2 (Buy) right now.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.